FINE SURGICAL INSTRUMENTS *British Made*

Macarthys
SURGICAL LIMITED



Cloward Laminectomy Disc Punch
⅔rd scale

Send for catalogue

Macarthys Surgical Limited

DAGENHAM: Selinas Lane, Dagenham, Essex RM8 1QD. Tel.: 01-593 7511
BIRMINGHAM: Units 25/28, Edgbaston Shopping Centre, Hagley Road, Birmingham B16 8SH. Tel.: 021-454 6713
LIVERPOOL: 201-3 London Road, Liverpool L3 8JG. Tel.: 051-207 1348
MANCHESTER: Precinct Centre, Oxford Road, Manchester M13 9GS. Tel.: 061-273 6754/5
SCOTLAND: 36 Telford Road, Lenziemill, Cumbernauld, Glasgow G67 2AX. Tel.: 02367-25051/2

A new era in the treatment of Parkinson's disease begins . . .

In 1970, the arrival of L-dopa revolutionised the treatment of Parkinson's disease. This was followed, in 1973 and 1979, by the highly successful combinations with peripheral decarboxylase inhibitors.

Now, in 1983, there is Eldepryl

Eldepryl is a new, selective inhibitor of the enzyme responsible for dopamine breakdown in the brain. Used in conjunction with L-dopa preparations, it provides the next logical step in treatment – dopamine conservation

The patient benefits of Eldepryl are substantial – Daily L-dopa intake can be immediately cut by 20% in most cases,[1] reducing unwanted side effects and extending the useful life of L-dopa. Eldepryl significantly reduces akinesia, and has been shown to smooth out "on-off" effects.

With Eldepryl, there is no complicated dosage regime to remember, simply one tablet daily, together with a 20% reduction of L-dopa on the first day of treatment, is usually all that is required.

ELDEPRYL®

selegiline hydrochloride

Conserves cerebral dopamine

PRESCRIBING INFORMATION

Presentation [illegible] **Indications** [illegible] **Dosage** [illegible] symptoms are very [illegible] **CONTRA-INDICATIONS, WARNINGS ETC. Contra-indications** There are no known contra-indications [illegible] **Warnings** Because Eldepryl potentiates the effects of levodopa the side effects of levodopa might be [illegible] When Eldepryl is added to maximally tolerated levodopa treatment [illegible] movements and agitation may [illegible] levodopa treatment can be reduced by an average of 30% [illegible] when Eldepryl is added to the treatment. When an optimal levodopa dose has been established the side effects of the combination are fewer than for levodopa alone. **Side Effects** Hypotension and nausea have been reported as isolated symptoms associated with Eldepryl treatment. Confusion or psychosis have also been reported. **Legal Category** POM **Product Licence Number** 4483 0024 **Basic NHS Cost** Pack of 100 tablets £30.00 **Reporting of Adverse Reactions** As a recently introduced product, any suspected adverse reactions should be reported to the Committee on Safety of Medicines, preferably on a yellow card. **Date of Preparation** October 1982

1. J. Neural Transmission 1976, 43, 245-251. J. Neural Transmission 1976, 36, 303-326.

Further information is available on request from Britannia Pharmaceuticals Limited, Lonsdale House, 7-11 High Street, Reigate, Surrey RH2 9RR.

4+1 the right balance in Parkinson's disease

Presentation
Madopar contains a combination of levodopa and the decarboxylase inhibitor benserazide in the ratio of 4:1. Madopar 62·5 capsules containing 50mg levodopa and 14·25mg benserazide hydrochloride (equivalent to 12·5mg of the base). Madopar 125 capsules containing 100mg levodopa and 28·5mg benserazide hydrochloride (equivalent to 25mg of the base). Madopar 250 capsules containing 200mg levodopa and 57mg benserazide hydrochloride (equivalent to 50mg of the base).

Indications
Parkinsonism – idiopathic, post-encephalitic.

Dosage
Dosage is variable and the data sheet should be consulted for full details. The effective daily dose usually lies between four and eight capsules of Madopar 125 (two to four capsules of Madopar 250) daily in divided doses, most patients requiring no more than six capsules of Madopar 125 daily. In some elderly patients initial treatment with one capsule of Madopar 62·5 once or twice daily, increasing by one capsule every third or fourth day may suffice. Patients who experience fluctuations in response may also benefit from administration of smaller more frequent doses using Madopar 62·5.

Contra-indications
Narrow-angle glaucoma, severe psychoneuroses or psychoses. It should not be given: in conjunction with monoamine oxidase inhibitors or within two weeks of their withdrawal; to patients under 25 years of age, to pregnant women; or to patients who have a history of, or who may be suffering from, a malignant melanoma.

Precautions
Drugs which interfere with central amine mechanisms should be avoided. Endocrine, renal, pulmonary or cardiovascular disease, hepatic disorder, peptic ulcer, osteoporosis, sympathomimetic drugs, antihypertensive drugs. Patients who improve on Madopar therapy should be advised to resume normal activities gradually as rapid mobilisation may increase the risk of injury.

Side-effects
Nausea and vomiting; cardiovascular disturbances; psychiatric disturbances; involuntary movements.

Packings
Madopar 62·5 capsules, Madopar 125 capsules and Madopar 250 capsules in packings of 100.

Licence Numbers
0031/0125 (Madopar 62·5 capsules); 0031/0073 (Madopar 125 capsules); 0031/0074 (Madopar 250 capsules).

Basic NHS Cost
Madopar capsules 62·5
£5·41 per 100
Madopar capsules 125
£9·76 per 100
Madopar capsules 250
£17·47 per 100

ROCHE

Roche Products Limited
PO Box 8
Welwyn Garden City
Hertfordshire AL7 3AY

Madopar is a trade mark
J522210/283

Madopar

the original 4+1 combination in three dosage forms, 62·5, 125 *and* 250



NEW
Stesolid
Diazepam-without the needle
Stesolid
diazepam
10 mg
For rect
Batch N
Stesolid from Weddel.
pt of rectal administration
diazepam.
Stesolid is a unique system that
obviates the need for needle in a
variety of conditions and procedures.
Status Epilepticus–no needle
Febrile convulsions–no needle
Minor procedures of all types–no needle
There are two strengths Stesolid 5 mg and Stesolid 10 mg
cribing Guidelines
ntation: White, rectal tubes contain solution of 2 mg/ml or 4
of 5 mg or 10 mg diazepam. Uses: Diaze nticonvulsant, sedative and
epileptic and febrile convulsions, teta dative in minor surgical
intravenous injection is impracticable Stesolid rectal tubes
Dosage and Administration: Sensitivit ries with age. Children:
Elderly patients – One 5 mg tube. Highe may be required in some patient
indications: Known sensitivity to diaz m. Acute pulmonary insufficiency. Pr
chronic pulmonary insufficiency or closed-angle glaucoma. Alertness and per
machinery. Alcohol may potentiate effects. Diazepam may enhance the effects
the safety of diazepam in human pregnancy. It should not be used, especially du
Diazepam is excreted in breast milk and therefore its use during lactation shoul
most common side-effects are drowsiness, light-headedness, unsteadiness
Precautions: Stesolid rectal tubes should be stored in a cool place. Legal Cat
5 x 10 mg tubes £4.25. Product Licence Numbers: 5 mg rectal tube 0495/0029
Further information is available from:
Weddel
pharmaceuticals
limited
Red Willow Road, Wrexham Industrial Estate

Published by British Medical Association, Tavistock Square, London WC1H 9JR
and printed in England by Eyre & Spottiswoode Ltd, Thanet Press, Margate